Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 4Ovarian Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Small Cell Lung Carcinoma 2Melanoma 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Rectal Diseases 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Stromal Tumors 1

Interventions

pembrolizumab 91Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 25Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × guadecitabine × Clear all
NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Fox Chase Cancer Center

Phase 2 Active not recruiting
21 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡